BR112023000406A2 - Combinação de zibotentan e dapagliflozina - Google Patents
Combinação de zibotentan e dapagliflozinaInfo
- Publication number
- BR112023000406A2 BR112023000406A2 BR112023000406A BR112023000406A BR112023000406A2 BR 112023000406 A2 BR112023000406 A2 BR 112023000406A2 BR 112023000406 A BR112023000406 A BR 112023000406A BR 112023000406 A BR112023000406 A BR 112023000406A BR 112023000406 A2 BR112023000406 A2 BR 112023000406A2
- Authority
- BR
- Brazil
- Prior art keywords
- zibotentan
- combination
- dapagliflozin
- treatment
- endothelin
- Prior art date
Links
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title abstract 3
- FJHHZXWJVIEFGJ-UHFFFAOYSA-N N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide Chemical compound COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=2OC=NN=2)C=C1 FJHHZXWJVIEFGJ-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003834 dapagliflozin Drugs 0.000 title abstract 3
- 229950003684 zibotentan Drugs 0.000 title abstract 3
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 2
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 2
- 102000002045 Endothelin Human genes 0.000 abstract 1
- 108050009340 Endothelin Proteins 0.000 abstract 1
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 abstract 1
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063050147P | 2020-07-10 | 2020-07-10 | |
| US202163196793P | 2021-06-04 | 2021-06-04 | |
| PCT/IB2021/056177 WO2022009163A1 (en) | 2020-07-10 | 2021-07-09 | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023000406A2 true BR112023000406A2 (pt) | 2023-01-31 |
Family
ID=76959008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023000406A BR112023000406A2 (pt) | 2020-07-10 | 2021-07-09 | Combinação de zibotentan e dapagliflozina |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US11730735B2 (https=) |
| EP (1) | EP4178578A1 (https=) |
| JP (1) | JP7814368B2 (https=) |
| KR (1) | KR20230038234A (https=) |
| CN (2) | CN119386017A (https=) |
| AU (2) | AU2021305983B2 (https=) |
| BR (1) | BR112023000406A2 (https=) |
| CA (1) | CA3188345A1 (https=) |
| CL (1) | CL2023000097A1 (https=) |
| CR (1) | CR20230083A (https=) |
| DO (1) | DOP2022000301A (https=) |
| IL (1) | IL299568A (https=) |
| MX (1) | MX2023000276A (https=) |
| PE (1) | PE20230778A1 (https=) |
| PH (1) | PH12023550025A1 (https=) |
| TW (1) | TWI900606B (https=) |
| UY (1) | UY39321A (https=) |
| WO (1) | WO2022009163A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022009163A1 (en) * | 2020-07-10 | 2022-01-13 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
| AU2023321653A1 (en) * | 2022-08-12 | 2025-03-27 | Astrazeneca Ab | Combination therapies for treatment of cirrhosis with portal hypertension |
| UY40633A (es) * | 2023-02-08 | 2024-07-31 | Astrazeneca Ab | Combinación de zibotentán y dapagliflozina para el tratamiento de la enfermedad renal crónica con pr |
| WO2025133907A1 (en) * | 2023-12-18 | 2025-06-26 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of microvascular angina |
| WO2025163559A1 (en) | 2024-02-01 | 2025-08-07 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for use for the treatment of hypertension |
| WO2025261457A1 (zh) * | 2024-06-21 | 2025-12-26 | 深圳信立泰药业股份有限公司 | 内皮素a(eta)受体拮抗剂联用sglt-2抑制剂的医药用途 |
| WO2026078068A1 (en) * | 2024-10-09 | 2026-04-16 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease and liver fibrosis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA58494C2 (uk) | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| EP2545920A1 (en) | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| US9364458B2 (en) | 2013-07-08 | 2016-06-14 | Abbvie Inc. | Stabilized pharmaceutical dosage forms comprising atrasentan |
| US8962675B1 (en) | 2013-09-12 | 2015-02-24 | Abbvie Inc. | Atrasentan mandelate salts |
| FI3658140T3 (fi) | 2017-02-27 | 2025-08-12 | Idorsia Pharmaceuticals Ltd | Aprositentaanin yhdistelmiä muiden vaikuttavien ainesosien kanssa resistentin verenpainetaudin hoitamiseksi |
| CN111405899B (zh) | 2017-11-30 | 2025-05-16 | 爱杜西亚药品有限公司 | 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与sglt-2抑制剂的组合 |
| US20210338648A1 (en) * | 2018-10-01 | 2021-11-04 | Astrazeneca Ab | Methods and compositions for reducing serum uric acid |
| IL297208A (en) | 2020-04-10 | 2022-12-01 | Chinook Therapeutics Inc | Treatment methods for diabetic kidney disease |
| WO2022009163A1 (en) * | 2020-07-10 | 2022-01-13 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
| US12409186B2 (en) | 2020-07-27 | 2025-09-09 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
-
2021
- 2021-07-09 WO PCT/IB2021/056177 patent/WO2022009163A1/en not_active Ceased
- 2021-07-09 PE PE2023000028A patent/PE20230778A1/es unknown
- 2021-07-09 MX MX2023000276A patent/MX2023000276A/es unknown
- 2021-07-09 TW TW110125259A patent/TWI900606B/zh active
- 2021-07-09 PH PH1/2023/550025A patent/PH12023550025A1/en unknown
- 2021-07-09 CA CA3188345A patent/CA3188345A1/en active Pending
- 2021-07-09 BR BR112023000406A patent/BR112023000406A2/pt unknown
- 2021-07-09 KR KR1020237004545A patent/KR20230038234A/ko active Pending
- 2021-07-09 IL IL299568A patent/IL299568A/en unknown
- 2021-07-09 CN CN202411625959.4A patent/CN119386017A/zh active Pending
- 2021-07-09 JP JP2023501052A patent/JP7814368B2/ja active Active
- 2021-07-09 EP EP21742896.0A patent/EP4178578A1/en active Pending
- 2021-07-09 CR CR20230083A patent/CR20230083A/es unknown
- 2021-07-09 CN CN202180049043.7A patent/CN115803028A/zh active Pending
- 2021-07-09 AU AU2021305983A patent/AU2021305983B2/en active Active
- 2021-07-09 US US17/371,162 patent/US11730735B2/en active Active
- 2021-07-12 UY UY0001039321A patent/UY39321A/es unknown
-
2022
- 2022-12-29 DO DO2022000301A patent/DOP2022000301A/es unknown
-
2023
- 2023-01-10 CL CL2023000097A patent/CL2023000097A1/es unknown
- 2023-06-23 US US18/213,601 patent/US12121517B2/en active Active
-
2024
- 2024-07-05 US US18/764,612 patent/US12409174B2/en active Active
- 2024-07-17 AU AU2024204913A patent/AU2024204913A1/en active Pending
-
2025
- 2025-08-11 US US19/296,221 patent/US20260027112A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12023550025A1 (en) | 2024-03-11 |
| CN115803028A (zh) | 2023-03-14 |
| CA3188345A1 (en) | 2022-01-13 |
| TWI900606B (zh) | 2025-10-11 |
| AU2024204913A1 (en) | 2024-08-01 |
| EP4178578A1 (en) | 2023-05-17 |
| US20240358698A1 (en) | 2024-10-31 |
| IL299568A (en) | 2023-02-01 |
| JP2023541766A (ja) | 2023-10-04 |
| US20260027112A1 (en) | 2026-01-29 |
| CN119386017A (zh) | 2025-02-07 |
| US11730735B2 (en) | 2023-08-22 |
| US20230364077A1 (en) | 2023-11-16 |
| TW202216147A (zh) | 2022-05-01 |
| AU2021305983A1 (en) | 2023-03-02 |
| WO2022009163A1 (en) | 2022-01-13 |
| AU2021305983B2 (en) | 2024-05-16 |
| CL2023000097A1 (es) | 2023-09-01 |
| CR20230083A (es) | 2023-05-16 |
| PE20230778A1 (es) | 2023-05-09 |
| US20220023295A1 (en) | 2022-01-27 |
| UY39321A (es) | 2022-01-31 |
| JP7814368B2 (ja) | 2026-02-16 |
| US12409174B2 (en) | 2025-09-09 |
| DOP2022000301A (es) | 2023-01-31 |
| KR20230038234A (ko) | 2023-03-17 |
| US12121517B2 (en) | 2024-10-22 |
| MX2023000276A (es) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023000406A2 (pt) | Combinação de zibotentan e dapagliflozina | |
| Yaqinuddin et al. | Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents | |
| Abdul-Aziz et al. | Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis | |
| Lehmann et al. | Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models | |
| Suzuki et al. | Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells | |
| Strand et al. | A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee | |
| Farinola et al. | Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema | |
| Bar-Yehuda et al. | The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis | |
| Mohammadpour et al. | Trachoma: Past, present and future | |
| Finney et al. | Differences in lipopolysaccharide-and lipoteichoic acid-induced cytokine/chemokine expression | |
| Zhang et al. | The mechanism of nicotinamide on reducing acute lung injury by inhibiting MAPK and NF-κB signal pathway | |
| BR112023016680A2 (pt) | Terapias de combinação com anticorpos anti-cd38 e parp ou inibidores de receptor de adenosina | |
| BRPI0622073A8 (pt) | Uso de anticorpos pdgfralfa para fabricação de um medicamento para tratar um tumor ósseo | |
| Armstrong et al. | Epidemiology of classic and AIDS-related Kaposi's sarcoma in the USA: incidence, survival, and geographical distribution from 1975 to 2005 | |
| BRPI0606996A2 (pt) | combinação de compostos orgánicos, uso da mesma e composição farmacêutica | |
| Park et al. | Poly I: C inhibits cell proliferation and enhances the growth inhibitory effect of paclitaxel in oral sqaumous cell carcinoma | |
| Yong et al. | Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway | |
| Sakakibara-Konishi et al. | Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer | |
| Shen et al. | Angiotensin-(1–7) attenuates SARS-CoV2 spike protein-induced interleukin-6 and interleukin-8 production in alveolar epithelial cells through activation of Mas receptor | |
| Chan et al. | Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis | |
| Mita et al. | An alternative index for evaluating AMU and anti-methicillin-resistant Staphylococcus aureus agent use: A study based on the National Database of Health Insurance Claims and Specific Health Checkups data of Japan | |
| Baker et al. | Recombinant human C1-esterase inhibitor to treat acute hereditary angioedema attacks in adolescents | |
| Shigemi et al. | Novel leukemic cell lines resistant to clofarabine by mechanisms of decreased active metabolite and increased antiapoptosis | |
| Pfirrmann et al. | No differences in molecular relapse-free survival after stopping imatinib treatment of chronic myeloid leukemia between patients with prior 4.5 log reduction (MR4. 5) but detectable and patients with undetectable disease in the EURO-SKI trial | |
| Cimica et al. | Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen |